UBS AM’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

UBS AM’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,670	Closed	-$192K	–	2701
2017 Q4	$192K	Buy	+10,670	New	+$131K	﹤0.01%	2326
2016 Q4	–	Sell	-13,159	Closed	-$162K	–	2788
2016 Q3	$162K	Hold	13,159	–	–	﹤0.01%	2510
2016 Q2	$144K	Buy	+13,159	New	+$147K	﹤0.01%	2534

Other funds holding SCMP

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AIM

Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

UBS AM's SCMP Position: Q1 2018 in Review

UBS AM sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 10,670 shares — an estimated $192K sold.

UBS AM first reported a position in SCMP in Q2 2016 and held it in 3 quarters. The position peaked at $192K in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.

UBS AM reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
UBS AM sold 10,670 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $192K.
UBS AM first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2016 and held it in 3 quarters.
UBS AM's Sucampo Pharmaceuticals, Inc. position peaked at $192K in Q4 2017.
3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.

Based on UBS AM's 13F filing for Q1 2018, filed 14 May 2018.